Kheiri B, et al. - Via this meta-analysis of eight randomized controlled trials (involving 633 total patients), researchers assessed whether carvedilol serves as an effective primary preventive strategy against the development of anthracycline-induced cardiotoxicity among cancer patients. The included studies were identified through a comprehensive search of electronic databases. These studies were focused on the occurrence of low left ventricular (LV) ejection fraction (EF) and the absolute change in LVEF, respectively. Findings suggested that, in anthracycline-treated cancer patients vs placebo-treated patients, prophylactic administration of carvedilol may attenuate the early onset of LV dysfunction.